Investing.com - Biomarin Pharma reported on Wednesday first quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Biomarin Pharma announced earnings per share of $0.63 on revenue of $519.4M. Analysts polled by Investing.com EPS of $0.2024 on revenue of $511.08M.
Biomarin Pharma 's are down 45.16% and is trading at $82.00 , still down 14.75% from its 52 week high of $94.20 set on Thursday, February 10, 2022.
Biomarin Pharma shares gained 2.10% to trade at $82.00 in after-hours trade the report.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma's report follows an earnings beat by UnitedHealth on Thursday, April 14, 2022, who reported EPS of $5.49 on revenue of $80.15B, EPS of $5.36 on revenue of $78.73B.
J&J had beat expectations on Tuesday, April 19, 2022 with first quarter EPS of $2.67 on revenue of $23.43B, for EPS of $2.59 on revenue of $23.62B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar